Krystal Biotech to Present at the American Thoracic Society 2024 International Conference

Rhea-AI Summary

Krystal Biotech (NASDAQ: KRYS), a commercial-stage biotechnology company, announced its participation in the American Thoracic Society (ATS) 2024 International Conference from May 17-22 in San Diego, CA. The company will present new preclinical data on respiratory genetic medicine candidates KB407 and KB408. Both are modified, replication-defective, non-integrating HSV-1 vectors designed for inhaled lung delivery via nebulization. KB407 aims to treat cystic fibrosis, while KB408 targets alpha-1 antitrypsin deficiency. Data on these candidates will be shared, including insights from ongoing Phase 1 studies. Poster presentations by Dr. Sara Artusi will provide further details.

Positive

• Krystal Biotech is presenting at a major conference, increasing visibility among peers and investors.
• New preclinical data on KB407 and KB408 could bolster confidence in their pipeline.
• Active Phase 1 studies indicate progress in clinical development.
• KB407's and KB408's novel approach (inhaled delivery) could offer significant therapeutic advantages.

Negative

• KRYS is still in the preclinical and early clinical trial phases for these candidates, indicating that market approval is years away.
• No financial data or revenue projections are provided, limiting investor insight into near-term financial performance.
• Success in preclinical data does not guarantee positive outcomes in clinical trials.

PITTSBURGH, May 15, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new preclinical data on respiratory genetic medicine candidates KB407 and KB408 at the American Thoracic Society (ATS) 2024 International Conference being held from May 17-22, 2024 in San Diego, California.

KB407 and KB408 are modified, replication-defective, non-integrating HSV-1 vectors formulated for inhaled delivery to the lung via nebulization. KB407 encodes two full-length copies of cystic fibrosis transmembrane conductance regulator (CFTR) and is under investigation for the treatment of cystic fibrosis irrespective of underlying patient mutation. KB408 encodes two full-length copies of alpha-1 antitrypsin and is under investigation for the treatment of alpha-1 antitrypsin deficiency (AATD).

Both KB407 and KB408 are being evaluated in ongoing Phase 1 studies.

Data presented at ATS will include new preclinical data related to KB407 transduction of fully differentiated, patient airway epithelial cell-derived apical out airway organoids and production of full-length and fully glycosylated CFTR, as well as an overview of KB408 IND-enabling studies conducted to support initiation of the ongoing Phase 1 SERPENTINE-1 study in patients with AATD.

Poster presentation details are as follows:

Title: Murine Toxicology Study of Repeat-Dose Inhaled KB408, an HSV-1-Based Vector for the Treatment of Alpha-1 Antitrypsin Deficiency
Presenter: Sara Artusi, PhD
Date and Time: May 20, 2024 from 11:30AM to 1:15PM PT
Poster Session: B70: COPD in the Spotlight: Insights into Disease Pathogenesis
Poster Number: P659

Title: Evaluation of KB407, an HSV-1-Based Gene Therapy Vector for the Treatment of Cystic Fibrosis, in Healthy and Patient-Derived Airway Cells Including an Apical-out Diseased Airway Organoid Model
Presenter: Sara Artusi, PhD
Date and Time: May 21, 2024 from 11:30AM to 1:15PM PT
Poster Session: C70: From Buds to Breath: Mechanisms and Pathogenesis of Lung Development
Poster Number: P122

The posters will be available to conference attendees. Following the presentation, the posters will also be available to view online on the Investor section of the Company’s website.

About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK^® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).

CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com

FAQ

What is Krystal Biotech presenting at the ATS 2024 International Conference?

Krystal Biotech will present new preclinical data on its respiratory genetic medicine candidates, KB407 and KB408.

What are KB407 and KB408?

KB407 is aimed at treating cystic fibrosis, and KB408 targets alpha-1 antitrypsin deficiency. Both use modified HSV-1 vectors for inhaled delivery.

When and where is the ATS 2024 International Conference?

The ATS 2024 International Conference will be held from May 17-22, 2024, in San Diego, California.

What will be included in the ATS conference presentations by Krystal Biotech?

Presentations will include new preclinical data on KB407 and KB408, details of Phase 1 studies, and poster sessions led by Dr. Sara Artusi.

What are the details of the poster presentations by Krystal Biotech at ATS 2024?

One presentation will be on May 20, 2024, discussing KB408, and another on May 21, 2024, focusing on KB407. Both will feature insights from ongoing studies.